CMS finalizes GLOBE Medicare drug price demo with lower savings
· Health · United States
The Centers for Medicare & Medicaid Services finalized its GLOBE demonstration aimed at lowering Medicare drug prices, but with expected savings far below earlier projections. A final rule on doctor-administered drugs applies to only four companies and saves 96% less than the initial proposal.
Why it matters：The scaled-back savings show how hard it is to translate drug-pricing ambitions into federal policy, affecting payers, manufacturers and patients.
Key points
- Expected savings trail earlier projections.
- The final rule covers only four companies.
- Savings are 96% less than the initial proposal.
Sources (original reporting)
More stories from this day
- Sanofi pays Regeneron $1B to expand antibody alliance
- Patient death clouds Bristol Myers fibrosis drug ahead of readout
- Devoted Health raises $1.2B as Medicare Advantage growth accelerates
- HHS launches programs to speed clinical trials amid China competition
- US and South Korea outline $120bn plan for eight nuclear units
- US, South Korea agree $120bn framework for eight nuclear reactors